By Jeff Newman, Esq., MBA, with AI assistance
This is about another important federal case in Philadelphia, this
one about GLP-1 side effects and alleged harm to patients.
In Courtroom 16B of the federal courthouse in Philadelphia, Judge
Karen Spencer Marston of the U.S. District Court for the Eastern
District of Pennsylvania presides over a closely watched druginjury proceeding: In re: Glucagon-Like Peptide-1 Receptor
Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094.
The defendants are two of the largest pharmaceutical companies in
the world, Novo Nordisk and Eli Lilly. The products are the drugs
that have changed how America thinks about weight: Ozempic,
Wegovy, Rybelsus, Victoza and Saxenda from Novo Nordisk, and
Mounjaro, Zepbound and Trulicity from Lilly.
The plaintifffs number in the thousands: 4,082 pending actions,
according to the Judicial Panel on Multidistrict Litigation’s report
of November 2, 2026. Most say the drugs slowed their digestion so
much that they suffered gastroparesis, sometimes called “stomach
paralysis.” Others allege bowel obstruction, ileus (a halt in the gut’s
normal movement), gallbladder disease and other injuries. The
companies deny that their warnings were inadequate and deny
liability.
This article covers what the case is about, what each side says, and
what the medical science actually shows. It also explains why the
most important decision so far may be one that hasn’t been made
yet. It does not argue a side. The drugs have helped a great many
people, and the evidence for those benefits is among the strongest
in modern medicine. The question in Philadelphia is narrower and
harder: whether the companies told doctors and patients enough
about the serious end of the drugs’ side-effect spectrum, and
whether that serious end is real.
Why Philadelphia?
When thousands of similar lawsuits are filed across the country, the
federal Judicial Panel on Multidistrict Litigation can send them to a
single judge for coordinated pretrial proceedings. That is a
“multidistrict litigation,” or MDL. In February 2024, the Panel sent
the GLP-1 cases to the Eastern District of Pennsylvania. The court’s
docket shows they were first assigned to Judge Gene E.K. Pratter.
After Judge Pratter’s death, they were reassigned to Judge Marston
in June 2024.
Philadelphia has since become the hub for GLP-1litigation more
broadly. In December 2025 the Panel created a second GLP-1 MDL,
No. 3163, also assigned to Judge Marston. It concerns claims of a
sudden form of vision loss called non-arteritic anterior ischemic
optic neuropathy, or NAION, which occurs when blood flow to the
front of the optic nerve drops. On November 9, 2026, the FDA
required the makers of every GLP-1 drug to add a warning about
NAION to the “Warnings and Precautions” section of their labels.
The agency concluded there is “a potential increased risk of rare
NAION events” in patients taking the drugs.1
An MDL is not a class action. Each plaintiff keeps an individual
lawsuit, files a “short form complaint,” and seeks individual
damages. What gets consolidated is the common work: discovery of
company documents, the battle over expert witnesses, and rulings
on legal questions that cut across all the cases. Those cross-cutting
rulings can decide the fate of thousands of claims at once. That is
why the current phase matters so much.
Philadelphia is a fitting place for this fight. For generations its
federal court has been where major questions of corporate conduct
and public health get tested in open court, as guided by the rules of
evidence, and where both sides are heard. The Panel has sent some
of the country’s largest mass-injury and drug cases here:
Fen-phen (MDL 1203).
In December 1997 the Panel sent thе
federal fen-phen diet-drug cases to Philadelphia. Plaintiffs
claimed the weight-loss combination damaged heart valves.
In August 2000, Judge Louis C. Bechtle approved a
nationwide class settlement with American Home Products,
later Wyeth, reported at $3.75 billion. Judge Harvey Bartle III
later took over the case and oversaw amendments to the
settlement. A generation before GLP-1 drugs, the same
courthouse handled the last great weight-loss-drug litigation.
Avandia (MDL 1871). In October 2007, the Panel centralized
claims that GlaxoSmithKline’s diabetes drug Avandia raised
the risk of heart attacks, before Judge Cynthia M. Rufe. The
Third Circuit’s 2019 decision in that litigation, on when court
records may be kept secret, is now being applied in the GLP-1
case (see “The Fight Over What the Public Gets to See,”
below).
Zoloft (MDL 2342). Plaintiffs claimed that Pfizer’s
antidepressant, taken during pregnancy, caused birth defects.
Judge Rufe excluded the plaintiffs’ general-causation experts
in 2014 and 2015 and entered summary judgment for the
defense in more than 300 cases in April 2016. The Third
Circuit afffirmed in 2017. The MDL closed in 2018 with no
global settlement.
Tylenol (MDL 2436). From 2013, Judge Lawrence F. Stengel
presided over claims that Tylenol caused liver damage at or
near recommended doses, including rulings on which experts
could testify. Now retired from the bench, Judge Stengel is
the court-appointed Special Master in the GLP-1 case.
NFL concussions (MDL 2323). Retired players alleged the
league concealed the long-term risks of repeated head
trauma. Judge Anita B. Brody gave final approval to a
settlement in April 2015, and the Third Circuit afMirmed in
2016. Settlement trackers report more than $1.7 billion in
awards payable as of November 2026. The case remains open,
now before Judge Joshua D. Wolson.
Asbestos (MDL 875). For 31 years, from July 1991 until it
closed in November 2022, Philadelphia was home to the
federal asbestos personal-injury docket, one of the largest
MDLs in federal history. Judges Charles R. Weiner, James T.
Giles and Eduardo C. Robreno presided in turn.
These cases ended in different ways. Fen-phen and the NFL cases
ended in large settlements. Zoloft ended when the judge excluded
the plaintiffs’ experts and the appeals court agreed. The court has
shown it can do both, which is why the expert rulings now pending
in the GLP-1 case draw so much attention.
What the Plaintiffs Allege
The plaintiffs’ key document is the Amended Master Long Form
Complaint, filed August 29, 2025 (ECF 481). It sets out the facts and
legal claims common to all plaintiffs, and each individual plaintiff’s
short form complaint adopts it. The complaint was initially filed
under seal; the court’s docket records that it was later “REPLACED
AND UNSEALED PER CHAMBERS”
The complaint names four defendants: Novo Nordisk A/S
(Denmark), Novo Nordisk Inc., Eli Lilly and Company, and Lilly
USA, LLC. Its core allegation is about the defendants’ warnings, not
about the existence of side effects:
“Defendants have acknowledged that gastrointestinal events
are well known side effects of the GLP-1 RA class of drugs.
However, Defendants have downplayed the nature, duration,
extent and seriousness of gastrointestinal events and failed to
warn about other adverse events caused by their GLP-1 RAs.”
(Complaint)
The complaint lists the injuries it says went unwarned. They
include debilitating cyclical vomiting requiring hospitalization,
gastroparesis, ileus, intestinal obstruction, gallbladder injury,
vitamin deficiency, Wernicke’s encephalopathy (a neurological
disorder caused by vitamin B1 deficiency), ischemic bowel
(damage from reduced blood flow to the intestine) and necrotizing
pancreatitis (a severe form of inflammation of the pancreas in
which part of the organ’s tissue dies).
The complaint does not just argue inadequate warnings. It devotes
long sections to the companies’ marketing. It alleges a campaign to
“medicalize” obesity and promotion for off-label weight-loss use
before the drugs were approved for it. It describes partnerships
with telehealth providers and coupon programs. It also argues the
drugs are less effective in real life than advertised, because many
patients stop taking them, some do not respond, and many regain
weight (Complaint 94-104). It pleads sixteen counts, from
failure to warn and negligence to fraud, consumer-protection
violations and wrongful death.
These are allegations; they have not been proven in court.
What the Companies Say
Both companies answered on December 9, 2025.
Novo Nordisk (ECF 554) admits the opening premise, that
“gastrointestinal events are well known side effects of the GLP-1
RA class.” It denies the rest of that paragraph and denies the
complaint’s allegations of wrongdoing. Among its defenses, Novo
pleads federal preemption: the argument that when the FDA
controls a drug’s label, state-law claims demanding a different
warning can be barred. That defense has become one of the most
contested issues in the case.
Eli Lilly (ECF 555) “denies any and all allegations of wrongdoing
and denies that Plaintiffs are entitled to any relief.” Lilly admits that
Trulicity is a GLP-1 medicine and that Mounjaro and Zepbound are
dual GLP-1/GIP medicines. It says it promotes them “consistent
with federal and state laws.” It also denies having anything to do
with Novo’s products.
The defense case is straightforward:
The FDA reviewed and approved the labels.
In STEP 1 (New England Journal of Medicine, 2021),1,961
adults with obesity but without diabetes took semaglutide 2.4
mg, the Wegovy dose, or placebo for 68 weeks. Average
weight change was -14.9% on semaglutide versus -2.4% on
placebo. Half the semaglutide group lost 15% or more of their
body weight.
In SURMOUNT-1 (NEJM, 2022),tirzepatide, the drug in
Mounjaro and Zepbound, produced average weight loss of
15.0%, 19.5% and 20.9% at its three doses, versus 3.1% on
placebo.
In SELECT (NEJM, 2023), 17,604 people with heart disease
and overweight but no diabetes took semaglutide or placebo.
Heart attack, stroke or cardiovascular death occurred in 6.5%
of the semaglutide group versus 8.0% оn placebo. The trial
reported a hazard ratio of 0.80, about a 20% lower risk over
time. In raw numbers, 1.5 fewer people in every 100 had one of
those eVents, which is about 19% fewer in relative terms.
A 2025 meta-analysis in the Journal of the American College
of Cardiology, pooling 21 randomized trials and 99,599
patients, found what its authors called “high-certainty
evidence” that GLP-1 drugs reduced death from all causes.
So the drugs are not marginal products. For many patients,
particularly those with diabetes or heart disease, the benefits are
substantial and well documented. The litigation does not dispute
that, and neither does this article.
The plaintiffs in these cases emphasize that when people stop
taking these drugs, the weight tends to come back:
In the STEP 1 extension, participants “regained two-thirds of
their prior weight loss” within a year of stopping.
In STEР 4, patients switched to placebo gained 6.9% while
those who stayed on semaglutide lost another 7.9%.
In SURMOUNT, patients switched from tirzepatide to
placebo regained 14.0% while those who stayed on it lost
another 5.5%.
And many people do stop. A 2025 study in JAMA Network Open of
125,474 U.S. adults found that 64.8% of patients without tyре 2
diabetes discontinued within one year.
Both sides use these facts. The companies say they show that
obesity is a chronic disease requiring ongoing treatment. The
plaintiffs say the drugs’ real-world benefits are smaller than
advertised because so many patients stop taking them, and they
cite research attributing much of that to gastrointestinal side
effects.
The Science of the Side Effect: Benefit and Risk Come
From the Same Place
Here are some critical facts about GLP-1 drugs and this case. These
drugs work partly by slowing the stomach. A slower stomach
keeps people feeling full and smooths out blood sugar after meals.
The slowing is part of how the drug works.
How much do they slow it? A small randomized trial published in
2023 measured gastric emptying with scintigraphy, a nuclear
imaging test that is the gold standard. Twenty women with obesity
received semaglutide 1.0 mg weekly or placebo for 12 weeks. Four
hours after a standard meal, 37% of the meal remained in the
stomachs of the semaglutide group, compared with none in the
placebo group. Half the meal took 171 minutes to empty, versus 118.
Compare that with how gastroparesis, a chronic digestive disorder
in which the stomach takes too long to empty into the small
intestine, is diagnosed. A 2026 review in JAMA by Mayo Clinic’s Dr.
Michael Camilleri describes the standard test: scintigraphy
showing more than 10% of a meal still in the stomach at four
hours, in a patient with symptoms. Under the American
Gastroenterological Association’s 2022 clinical practice update,
more than 35% retention is graded “severe.”
Set side by side, those two numbers are significant. Neither paper
makes this comparison; it is ours, and the trial had only 20
participants. Average retention on semaglutide in that trial fell in
the range that would grade a symptomatic patient’s gastroparesis
as severe. That cuts both ways:
For the plaintiffs, it shows the drug can produce stomach emptying results in the gastroparesis range.
For the defense, it means a gastroparesis test taken while a
patient is still on the drug may simply be measuring the drug
doing what it was designed to do. That is not a distinct
disease.
Camilleri review adds two relevant facts. First, among
gastroparesis cases in a study of 82.6 million U.S. patients, tyре 2
diabetes was the leading cause (51.7%), and medications
accounted for 11.8%. А diabetic patient on a GLP-1 drug therefore
has two plausible explanations for a slow stomach. Second, the
review lists stopping medications that slow the stomach,
including GLP-1 drugs, as part of treatment.
What the Studies Show About the Serious Side Effects
This is where the evidence gets genuinely mixed:
Randomized trials are the strongest design for proving cause
and effect. But they are usually too small and too short to
detect rare events, and they did not routinely test trial
participants for gastroparesis.
Observational studies of insurance claims and health
records are large enough to find rare events. But they cannot
fully rule out other explanations, and they often rely on
billing codes rather than clinical tests.
Gastroparesis
Sodhi et al., JAMA 2023. The best-known observational
study compared GLP-1 users with users of a different weightloss drug, bupropion-naltrexone. It reported a roughly 3.7-
fold higher risk of gastroparesis, a 4.2-fold higher risk of
bowel obstruction and a 9-fold higher risk of pancreatitis.
Some of those estimates had very wide margins of
uncertainty. Other researchers criticized the study in JAMA’s
own pages. They noted that an obesity diagnosis code doesn’t
prove the drug was taken for weight loss, and that the
pancreatitis finding conflicted with large trial analyses.
Aneke-Nash et al., BMJ Opеn Gastroenterology 2025. In
55,460 people with obesity and no diabetes, gastroparesis
was diagnosed at 6.5 per 1,000 person-years on semaglutide,
versus 2.1 on bupropion-naltrexone and 1.1 after sleeve
gastrectomy, a type of weight-loss surgery. The adjusted
hazard ratio was 3.33 versus bupropion-naltrexone.
Alkabbani et al., Diabetes, Obesity & Metabolism 2026. In
313,342 matched pairs of patients with type 2 diabetes, GLP-1
drugs were associated with a 37% higher rate of severe
constipation, gastroparesis or GI obstruction than another
diabetes drug class. But the absolute risk, meaning the actual
probability that the outcome happens to a person in the
group, was “1% or less.”
Chiang et al., Gastroenterology 2025.
Against these sits ameta-analysis of 55 randomized trials involving 106,395
people. It found GLP-1 drugs “probably have little or no
effect” on most serious gastrointestinal events, with the
eхсеption of gallstones and acid reflux.
There is also direct physical evidence that the stomach slows:
Panchal et al., Gastrointestinal Endoscору 2025, University
of Pennsylvania. Researchers from Penn’s Perelman School
of Medicine reviewed 598 endoscopy patients. Those on GLP1 drugs had higher odds of solid food remaining in the
stomach despite fasting (odds ratio 3.80) and more aborted
procedures (1.3% vs. 0%). There were no cases of pulmonary
aspiration.
Vlaeminck et al., Anaesthesia 2026. A prospective matched
study found a “full stomach” on ultrasound before surgery in
49% of semaglutide patients versus 18% of matched controls.
One question no one has answered: does gastroparesis caused by
these drugs ever continue in patients after they stop taking them?
A 2026 systematic review in PLoS One found 13 published case
reports of GLP-1-associated gastroparesis, and in every one,
stopping the drug led to resolution of symptoms. But 13 case
reports is a thin record. Gastroenterologists including Belgium’s Dr.
Jan Tack wrote in 2025 that while most effects are transient, “a
significant subset of patients develop persistent intolerance.”
The study that would answer that question does not yet exist:
patients followed with gastric-emptying tests before, during and
after stopping the drug.
Bowel obstruction and ileus:
the international picture
Some of the most useful evidence on obstruction comes from
outside the United States, and it points in different directions.
Scandinavia. National registers in Sweden, Denmark and
Norway covered 121,254 new GLP-1 users from 2013 to 2021.
Compared with users of another diabetes drug class, they had
no statistically significant increase in intestinal obstruction
(1.3 vs. 1.6 per 1,000 person-years). The authors wrote that
“previous safety signals … were not confirmed.”
Japan. A nationwide insurance-claims study from the
University of Tokyo covered 298,124 adults with type 2
diabetes. Of those, 25,779 started a GLP-1 drug and 272,345
started a different diabetes drug class, SGLT2 inhibitors. The
GLP-1 group had no increased risk of obstruction or ileus
serious enough to require tube decompression or surgery.
The rates were 0.14% vs. O.17% at one year.
Denmark, bowel-disease patients. A nationwide study of
patients with inflammatory bowel disease found no increased
risk of ileus or obstruction.
United Kingdom.
A 2022 study led from Montpellier, France,
using Britain’s Clinical Practice Research Datalink, did find
increased risk of obstruction requiring hospitalization (1.9 vs.
per 1,000 person-years; HR 1.69). The risk was highest
after about 1.6 years of use (HR 3.48). That is notable for
anyone asking about long-term effects. The authors
estimated one additional case for every 1,223 patients treated
for a year.
WHO global database. An analysis of the World Health
Organization’s adverse-event database found intestinal
obstruction reported about three times more often with GLP1 drugs than with other diabetes drugs. Voluntary reports like
these flag a possible signal; they cannot measure risk.
A 2026 review from Sweden’s Karolinska Institutet summed up the
state of the evidence: for pancreatitis and intestinal obstruction,
“evidence regarding causality remains uncertain.”
Gallbladder disease: the clearest signal
He et al., JAMAInternal Medicine 2022. Pooling 76
randomized trials with 103,371 patients, GLP-1 drugs were
associated with a 37% higher risk of gallbladder or bile-duct
disease. In weight-loss trials the risk was more than doubled
(RR 2.29), and it was higher at higher doses and with longer
use.
Chiang et al., Gastroenterology 2025. Confirmed an increase
in gallstones, about two more cases per 1,000 people.
Karolinska review, 2026. Gallbladder and biliary disease
“has the most consistent evidence supporting a causal
association.”
Pancreatitis
Meta-analyses of randomized trials generally do not show
increased pancreatitis risk with semaglutide or with long-acting
GLP-1 drugs in diabetes. The higher observational estimates
remain contested.
Is one company’s drug diffferent?
A large NIH-funded study in the Annals ofInternal Medicine
(2025) compared Trulicity, Ozempic and Mounjaro head to head in
adults with type 2 diabetes. Severe gastrointestinal events occurred
at similar rates across all three. That matters in a case against two
companies whose products the plaintiffs largely treat as a class.
Because every patient in that study took a GLP-1 drug, it does not
answer whether the class as a whole raises risk.
Misuse is its own risk
A 2026 report from France’s national pharmacovigilance system
described 72 serious harms tied to misuse of these drugs. The
patients were mostly young women, with a median age of 3О.
Overdosing was involved in three-quarters of the cases with dosing
information. In nearly two-thirds of cases the drug came from
outside the medical system: from relatives, social media, online
sources or the black market. Some injuries the MDL alleges,
including pancreatitis, paralytic ileus and gastroparesis, appear in
that series toо.
What the Labels Said, and When They Changed
The legal arguments center in part on warnings, so the timeline of
label changes matters. These dates come from public regulatory
records.
In the United States:
On September 20, 2023, the FDA approved adding ileus (an
impairment of the intestine’s muscle contractions that stalls
the movement of its contents) to the “Postmarketing
Experience” section of the Ozempic label. The Wegovy and
Mounjaro labels already reported ileus. The FDA used its
standard caveat, that because such reports come voluntarily
“from a population of uncertain size, it is not always possible
to reliably estimate their frequency or establish a causal
relationship to drug exposure.”
On October 14, 2025, after evaluating what it called a safety
signal for “intestinal obstruction and fecal impaction” across
the GLP-1 class, the FDA asked manufacturers to update their
labels. The FDA-approved labels for Trulicity (March 2026)
and Zepbound (2026) show two changes. First, a new
statement under “Severe Gastrointestinal Adverse Reactions”
that such reactions “have also been reported postmarketing
with GLP-1 receptor agonists.” Second, the addition of
“intestinal obstruction, severe constipation including fecal
impaction” to the postmarketing adverse reactions.
In Europe and elsewhere:
A 2020 issue of Germany’s independent drug bulletin arzneitelegramm reported that European product information for
GLP-1 agonists listed intestinal obstruction as a side effect,
occurring “very rarely to uncommonly.” A 2023 New Zealand
regulatory report described the European listing as covering
GLP-1 drugs “excluding semaglutide.”
European Medicines Agency records show that in February
2021 Europe added “delayed gastric emptying” to Trulicity’s
list of adverse reactions, as “rare.” In June 2024, the EMA’s
scientific committee adopted an opinion adding a warning
on gastroparesis to Trulicity’s European label, stating that
“events related to impaired gastric emptying, including
severe gastroparesis, have been reported.” The European
Commission formally adopted that change on July 23, 2025.
In September 2023, a report to New Zealand’s Medicines
Adverse Reactions Committee noted that “Medsafe has
previously requested data sheet updates for GLP-1 RAs to list
intestinal obstruction but this request was declined by
sponsors.” The staff report itself concluded: “There is limited
evidence of an increased risk of gastrointestinal obstruction
with GLP-1 RAs and DPP-4 inhibitors.” Even so, the
Committee itself, citing the drugs’ known effect on gut
motility, recommended updating New Zealand data sheets to
include the risk of intestinal obstruction, including ileus, for
the whole GLP-1 class.
What do these differences mean?
European and U.S. labeling standards and processes differ, and regulators reach different
judgments on the same data. Plaintiffs will argue that the earlier
European language shows what could have been said to
Americans. The companies will argue that the FDA, which had the
same information, made its own decisions about U.S. labels. The
court will have to sort that out.
The Courtroom Fight over Who Gets to Testify
In mass drug litigation, cases are often won or lost before any jury is
seated, at the stage where the judge decides which expert witnesses
may testify. Under Federal Rule of Evidence 702, the judge acts as
gatekeeper and admits only expert opinions that rest on reliable
methods properly applied.
That gatekeeping has already reshaped this case once. On August
15, 2025, Judge Marston ruled that any plaintiff claiming
gastroparesis “must show that their diagnosis is based on a
properly performed gastric emptying study (scintigraphy, breath
test, or WMC).” She excluded the opinions of two plaintiffs’ experts
who had argued that a diagnosis could be made without such
testing. Gastroparesis claims without such testing are now
vulnerable to dismissal.
The court then organized the next phase around two “crosscutting issues”. Issue 2 asks whether the companies’ warnings
were adequate and whether federal preemption bars the claims.
Issue 3 asks whether the drugs can cause the alleged injuries at all,
which lawyers call “general causation.” In May 2026, the judge ruled
that Issue 2 summary-judgment motions were not limited to the
four core injuries (gastroparesis, bowel obstruction, ileus and
gallbladder disease). They could also reach necrotizing
pancreatitis, micronutrient deficiencies, Wernicke’s
encephalopathy and aspiration.
On May 19, 2026, both companies moved to exclude the plaintiffs’
causation experts and for summary judgment. According to the
companies’ filings, the plaintiffs’ experts include
gastroenterologists, a pharmacologist, a veterinary pathologist who
evaluated animal studies, and two regulatory experts. One of the
regulatory experts is a former FDA medical reviewer. The other is
Dr. David Kessler, who served as FDA Commissioner from 1990
to 1997. The plaintiffs, in turn, moved to limit testimony from
several defense experts. Lilly wrote that gastroparesis claims “still
comprise more than 60% of the MDL cases against Lilly.”
The filings show how narrow the core dispute has become. NovO
told the court it was not moving to exclude the plaintiffs’
gastroenterology expert’s opinion that the drugs can cause
transient drug-induced gastroparesis. It challenged his opinion that
they cause gastroparesis that persists after the drug is stopped.
Novo’s brief quotes the expert as conceding that “there simply is no
reported literature of any kind” on prolonged or permanent
gastroparesis from these drugs. That gap is the same one the
medical literature shows.
The court held a five-day evidentiary hearing on the expert
challenges from September 14 to 18, 2026, and heard closing
arguments on October 13 and 14. As of the docket entries through
early November 2026, the judge had not ruled, and no bellwether
(test) trial had been scheduled. Her decision on which experts may
testify could shape, or shrink, the litigation more than anything else
in the case.
Jeff Newman Law is a national whistleblower law firm that handles whistleblower cases under the False Claims Act, including healthcare and tariff fraud matters and other kinds of cases. Reach the firm at www.jeffnewmanlaw.com or 617-823-3217.
Novo Roadmap Brief, ECF 675 (May 19, 2026)
Lilly Introductory Roadmap Brief, ECF 677 (May 19, 2026)
Novo Response in Opposition to Motion to Strike Preemption
Defense, ECF 761 (June 30, 2026)
Plaintiffs’ Reply in Support of Motion to Strike, ECF 841 (Aug.
7,2026)
Special Master’s Fourth Report and Recommendation, ECF
892 (Sept. 21, 2026)
Court docket entries through Nov. 6, 2026, including the Aug.
15, 2025 Memorandum Order, CMO 32, and the hearing
minute entries
Case Management Orders: paed.uscourts.gov MDL 3094
page
Judicial Panel on Multidistrict Litigation, MDL Statistics
Report, Distribution of Pending MDL Dockets by District
(Nov. 2, 2026):jpml.uscourts.gov
Other Eastern District of Pennsylvania MDLs
In re Diet Drugs
(Phentermine/Fenfluramine/Dexfenfluramine) Prods. Liab.
Litig., MDL 1203: memorandum reciting the JPML’s Dec. 1O,
1997 transfer and Judge Bechtle’s PTO 1415 settlement
approval (Aug. 28, 2000), govinfo.gov; $3.75 billion figure as
reported at the time, e.g. Nevada Appeal/NNBW; Judge
Bartle’s approval of the Seventh Amendment, FDAnews
In re Avandia Mktg., Sales Practices & Prods. Liab. Litig., MDL
1871: E.D. Pa. MDL page (JPML order Oct. 16, 2007; Judge
Rufe)
In re Zoloft (Sertraline Hydrochloride) Prods. Liab. Litig., MDL
2342: E.D. Pa. MDL page; Third Circuit No. 16-2247, 858 F.3d
787 (2017), opinion; JPML Recently Terminated MDLs report
(Sept. 17, 2018)
In re Tylenol (Acetaтіпоphen) Mktg., Sales Practices & Prods.
Liab. Litig., MDL 2436: CMO 6 (June 3, 2013);Judge Stengel’s
Rule 702 memorandum, July 28, 2016
In re National Football League Players’ Concussion Injury
Litig., MDL 2323: JPML Nov. 2, 2026 pending report;
CourtListener docket 2:12-md-02323; award totals from
Settlement Insight (secondary source)
In re Asbestos Prods. Liab. Litig. (No. VI), MDL 875: Robreno
opinion noting judge succession, govinfo.gov; CourtListener
JPML docket
Regulatory records
FDA Drug Safety Communication, “FDA requires safety
labeling changes for glucagon-like peptide-1 receptor
agonists (GLP-1 RAs) due to potential increased risk of rare
but serious eye condition” (Nov. 9, 2026), fda.gov; as reporteр
by Pharmacy Times and Healio
FDA-approved labeling, Trulicity BLA 125469 and Zepbound
NDA 217806 (2026), accessdata.fda.gov
Medsafe (New Zealand), MARC report, “GLP-1 receptor
agonists and DPP-4 inhibitors and the risk of gastrointestinal
obstruction” (meeting 195, Sept. 14, 2023), medsafe.govt.nz;
minutes of the 195th meeting, medsafe.govt.nz; “MARC’s
remarks: September 2023 meeting,” Prescriber Update 44(4)
(Dec. 2023), medsafe.govt.nz
arznei-telegramm 2020 (English translation)
FDA Drug Safety-related Labeling Changes (SrLC) database:
Ozempic (Sept. 20, 2023, ileus); Trulicity (severe
gastrointestinal adverse reactions, recent major change
03/2026); Zepbound (2026 label)
European Medicines Agency, Trulicity “Procedural steps
taken and scientific information after authorisation”: II/OO51
(opinion Feb. 11, 2021);II/0070 (opinion June 27, 2024;
Commission decision July 23, 2025)
Medical literature (via PubMed / National Library of Medicine)
Wilding et al., STEP 1, NEJM 2021,
doi:10.1056/NEJMoa2032183
Jastreboff et al., SURMOUNT-1, NEJM 2022,
doi:10.1056/NEJMoa2206038
Lincoff et al., SELECT, NEJM 2023,
doi:10.1056/NEJMoa2307563
Galli et al., ЈАСС 2025, doi:10.1016/j.jacc.2025.08.027
Wilding et al., STEР 1 extension, Diabetes Obes Metab 2022,
doi:10.1111/dom.14725
Rubino et al., STEP 4, JAMA 2021, doi:10.1001/jama.2021.3224
Aronne et al., SURMOUNT-4, JAMA 2024,
doi:10.1001/jama.2023.24945
Rodriguez et al., JAMA Netw Open 2025,
doi:10.1001/jamanetworkopen.2024.57349
Jensterle et al., Diabetes Obes Metab 2023,
doi:10.1111/dom.14944
Camilleri, “Gastroparesis: A Review,” JAMA 2026,
doi:10.1001/jama.2026.12181
Sodhi et al., JAMA 2023;330:1795–1797,
doi:10.1001/jama.2023.19574
Aneke-Nash et al., BMJ Ореn Gastroenterol 2025,
doi:10.1136/bmjgast-2024-001704
Alkabbani et al., Diabetes Obes Metab 2026,
doi:10.1111/dom.70963
Chiang et al., Gastroenterology 2025,
doi:10.1053/j.gastro.2025.06.003
Panchal et al., Gastrointest Endosc 2025,
doi:10.1016/j.gie.2025.01.004
Vlaeminck et al., Anaesthesia 2026, doi:10.1111/anae.70129
Olubodun et al., PLoS One 2026,
doi:10.1371/journal.pone.0354497
Masulli, Tack et al., Intern Emerg Med 2025,
doi:10.1007/s11739-025-04117-9
Ueda et al., Scandinavian cohort, Clin Gastroenterol Hepatol
2023, doi:10.1016/j.cgh.2023.08.034
Matsuo, Okada, Sakamoto, Yasunaga, “Bowel
Obstruction/Ileus Associated With the Use of Glucagon-Like
Peptide-1 Receptor Agonists: A Nationwide Database Study,”
Diabetes Obes Metab 2026;28(11):9941-9954,
doi:10.1111/dom.71189
Danish IBD cohort, Inflamm Bowel Dis 2025,
doi:10.1093/ibd/izae276
Faillie et al., UK CPRD, Clin Pharmacol Ther 2022,
doi:10.1002/cpt.2430
Gudin et al., VigiBase, Therapie 2020,
doi:10.1016/j.therap.2020.02.024
Karolinska review, J Intern Med 2026, doi:10.1111/joim.70170
He et al., AMA Intern Med 2022,
doi:10.1001/jamainternmed.2022.0338
Masson et al. 2024, doi:10.1016/j.endien.2024.03.012; Lee et al.,
Diabetes Care 2025, doi:10.2337/dc25-0241
Crisafulli et al., Ann Intern Med 2025, doi:10.7326/ANNALS25-01724
French pharmacovigilance misuse series, Br J Clin Pharmacol
2026, doi:10.1002/bcp.70908
Other
Harvard Medicine magazine, “David Kessler on What Doctors
and Patients Should Know About GLP-1 Drugs” (Summer
2025)
FDA Drug Safety Communication, November 9, 2026.
Because individual trials had few NAION cases, the FDA
pooled 126 randomized trials covering 134,253 patients.
NAION occurred at 6.4 events per 100,000 person-years on
GLP-1 drugs, versus 3.8 on comparison treatments. Realworld studies found a higher risk with GLP-1 drugs than with
one older class of diabetes drugs (DPP-4 inhibitors), but no
statistically significant difference from another (SGLT2
inhibitors). The FDA noted that NAION’s risk factors, such as
diabetes, high blood pressure and sleep apnea, overlap with
the conditions these drugs treat. It advised that patients who
develop NAION discuss with their doctor whether to
continue the drug.